Inactief instrument

Andere talen Cyteir Therapeutics, Inc.

Aandelen

CYTT

US23284P1030

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Cyteir Therapeutics, Inc. Estimates Common Stock Liquidation Distributions	20/03
Cyteir Therapeutics, Inc.(NasdaqGS:CYT) dropped from S&P TMI Index	20/03
Cyteir Therapeutics, Inc.(OTCPK:CYTT) dropped from NASDAQ Composite Index	15/03
Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq	07/03
Cyteir Therapeutics, Inc. Announces Resignation of Timothy Romberger from Board of Directors	07/12
Cyteir Therapeutics, Inc. Announces Board Changes	05/12
Cyteir Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	06/11
Cyteir Therapeutics - Ongoing Results from a Dose Expansion Cohort of CYT-0851 in Combination with Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile	13-10-23
Cyteir Therapeutics' Ovarian Cancer Combination Treatment Candidate Shows 91% Overall Disease Control in Phase 1 Study	12-10-23
Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile	12-10-23
Cyteir Therapeutics, Inc. Presents Ongoing Results from a Dose Expansion Cohort of CYT-0851 in Combination with Capecitabine in Advanced Platinum-Resistant Ovarian Cancer	12-10-23
Cyteir Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	07-08-23
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution	03-07-23
Top Midday Gainers	30-06-23
Cyteir Therapeutics, Inc. Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution	30-06-23
Cyteir Therapeutics to Discontinue CYT-0851 Development, Plans Dissolution, Liquidation of Assets; Shares Rise Pre-Bell	30-06-23
Cyteir Therapeutics' Board Recommends Liquidation, Dissolution of Assets	30-06-23
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution	30-06-23
CYTEIR THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	05-06-23
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile	03-06-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cyteir Therapeutics, Inc.

Aandelen

CYTT

US23284P1030

Andere talen

Filters